The Effect Of Food On The Pharmacokinetic Properties And Bioequivalence Of Two Formulations Of Levocetirizine Dihydrochloride In Healthy Chinese Volunteers.

PURPOSE: The aim of this study is to assess the bioequivalence of a new generic formulation and the branded formulation of levocetirizine dihydrochloride in healthy Chinese volunteers under fasting and fed conditions, and food-intake effect on the pharmacokinetic properties is also evaluated. PATIENTS AND METHODS: Volunteers were randomly allocated into two groups to receive a single oral dose of generic formulation and branded formulation under fasting or fed conditions, respectively. Blood samples were collected at designated time points. Plasma concentrations of levocetirizine were determined by UFLC-MS/MS. Safety evaluations were carried out through the study. The main pharmacokinetic parameters of the two formulations of levocetirizine were calculated using non-compartmental analysis incorporated in WinNonlin® 7.0 software.
RESULTS: Forty-nine volunteers were enrolled; 46 completed the studies. Under fasting and fed conditions, the 90% confidence intervals for the geometric mean of generic/branded ratios were in the range of 94.75-107.24% and 99.98-114.69% for the maximum observed concentration, and 97.13-102.50% and 98.36-103.98% for the area under the concentration-time curve. As a result of food intake before administration, the reduced rate and extent of absorption of levocetirizine were observed. Both formulations were generally well tolerated, with no serious adverse reactions reported.
CONCLUSION: The two formulations demonstrated essentially identical pharmacokinetic profiles and were all well within the FDA/CFDA bioequivalence standards. Meanwhile, food intake can delay the absorption rate and reduced the bioavailability of levocetirizine in healthy Chinese volunteers.

Introduction

Levocetirizine hydrochloride, the active R enantiomer of cetirizine hydrochloride, is a third-generation selective H1 receptor antagonist. The pharmacological effects of levocetirizine involve stabilizing the mast cell membrane, inhibiting early hypersensitivity reaction mediated by histamine, and depressing late anaphylaxis induced by eosinophils and basophils.1 It is widely used in the treatment of allergic diseases such as chronic urticaria, atopic dermatitis, allergic rhinitis, and allergic asthma.

Levocetirizine is rapidly and extensively absorbed after oral administration. It is eliminated by renal excretion to a larger extent.2 The in vivo metabolic pathway for levocetirizine consists of oxidative hydroxylation, oxy-dealkylation, glucuronic acid-binding, and glutathione binding to sulfate formation. Unlike other H1 receptor blockers, levocetirizine cannot penetrate the blood–brain barrier, which contributes to the weak central inhibitory effect. Although levocetirizine is well tolerated, some adverse effects were reported in patients under therapy with levocetirizine.3–5 Most of the adverse effects of levocetirizine were dose-dependent. For example, sedation was noted more significantly in the high-dose group.6 Inevitably, sometimes a higher dose of levocetirizine may be prescribed in the clinic.7,8 Therefore, levocetirizine may not be an absolutely safe drug, especially for the patients who need a high dose or the patients with liver and kidney dysfunction. It is of great importance to ensure the quality of generic formulation that is comparable with the branded formulation.

Pharmacokinetic parameters: the maximal plasma concentration (Cmax), the time to peak plasma concentration (Tmax), and the area under the plasma concentration–time curve (AUC) are routinely used to evaluate the bioequivalence between two formulations. These parameters can be influenced by several factors, including gender, age, genetics, and ethnicity, as well as the drug quality and formulation, drug–drug and drug–food interactions. With regard to drug–food interactions, concomitant food intake may affect the pharmacokinetic process. Food exerts multiple effects on the absorption of many orally administrated drugs.9 It is worth noting that food can alter the bioavailability of orally administered drugs by various means, including delayed gastric emptying, stimulated bile flow, altered pH value in the gastrointestinal tract, increased splanchnic blood flow, changed in the luminal metabolism of a drug substance, and physical or chemical interaction with a dosage form or a drug substance.10 Food effects on bioavailability can have clinically significant consequences, leading to variations in efficacy and toxicity. Furthermore, a generic formulation that is bioequivalent compared with a branded formulation under fasting condition does not necessarily mean bioequivalent under fed condition. Due to the different preparation technique or application of excipients or interactions between excipients and the food-induced changes in gut physiology can contribute to these food effects and influence the bioequivalence. Currently, however, the detailed information describing the effects of food on the pharmacokinetic properties of levocetirizine has not been documented in any papers. It is important to clarify whether concomitantly administered food affects the pharmacokinetics of levocetirizine and evaluate the bioequivalence of drugs in both fasting and fed conditions.

Bioequivalence between generic and branded drugs is an issue that affects both clinical use and health care costs.11 Whether the generic and branded drugs are interchangeable, and whether their clinical efficacy is equal, can be the key concern of both clinicians and patients. However, due to the past defective policy of the China Food and Drug Administration (CFDA), most of the generic drugs are not really proven to be bioequivalent. In fact, there are many generic drugs with poor quality in the market, which lack sufficient therapeutic efficacy. Fortunately, in order to improve the quality of generic drugs, CFDA issued a deadline that all generic drugs administrated by oral route should pass bioequivalence evaluation no later than 2018. Now several versions of generic levocetirizine tablets are available in China, but few of them have proved to be bioequivalent through clinical study in healthy volunteers. Here is a generic drug, levocetirizine hydrochloride in the form of tablet, that has been developed by Suzhou Downray Pharmaceuticals. The current study aims to compare the bioequivalence of the new generic formulation with the branded drug levocetirizine hydrochloride (Xyzal®) in healthy Chinese volunteers, as well as the food-intake effect on the pharmacokinetics of levocetirizine.

Materials And Methods

Volunteers

The study was aimed to enroll 48 healthy adult human volunteers (fasting: 24, fed: 24) according to the following criteria: (i) 18~65 years old (including 18 and 65 years) with a body mass index of 19.0~26.0 kg/m2 (including 19.0~26.0); (ii) Volunteers were in good health condition that had no significant clinical symptoms or abnormal laboratory values. The volunteers were excluded based on the following criteria: (i) Volunteers with significant laboratory abnormalities or other significant disease histories should be excluded; (ii) Volunteers allergic to two or more drugs and food, or active ingredients and excipients; (iii) Volunteers on any other drugs (including Chinese herbs) within two weeks of the study; (iv) Volunteers positive with Nicotine or urine screening; (v) Volunteers that had a history of alcohol, drug abuse and addiction; (vi) Volunteers with birth plans (including male volunteers) during the study or within three months of the end of the study; (vii) Blood donation history within one month before the study; (viii) Volunteers that has been resumed by investigators with poor compliance or unsuitable to the study. All the volunteers underwent a complete physical examination.

Study Design And Sample Collection

The study protocol was approved by the ethics committee of Fujian Union Hospital (no.2017YW009), and all aspects of the study complied with the Declaration of Helsinki, Good Clinical Practice (GCP) guidelines, and the law and regulations of the People’s Republic of China. Written informed consent was obtained from each volunteer.

A pilot study was performed before the formal study. A total of 8 healthy volunteers were involved in the pilot study (4 fastings and 4 feds). According to the results of the pilot bioequivalence study, a single-center, single-dose, open-label randomized two-arm self cross, and food effect study was designed to compare the bioequivalence of levocetirizine under fasting and fed conditions between the generic formulation (levocetirizine tablets, 5 mg, Suzhou Downray Pharmaceutical Co., Ltd., Lot No.: T150931001, purity: 98.5%) and the branded formulation (levocetirizine tablets, 5 mg, UCB Farchim S.A., Lot No.: 192626, purity: 99.8%). The random sequence was generated by gender using SAS 9.4. Eligible healthy volunteers who met the inclusion criteria obtained a unique volunteer number according to the succession of the enrollment, they were randomly assigned to either the generic-branded group or the branded-generic group by 1:1. The crossover part of the study was conducted after a 7-day wash-out period. The sample size of 24 volunteers in fasting or fed including 20% drop-outs would provide 80% power for AUC to ensure that the 90% confidence intervals (CIs) for the ratio of generic to branded according to Food and Drug Administration (FDA).12

In the fasting condition, after an overnight fast for at least 10 hrs, each volunteer received a single oral dose of 5 mg generic or branded formulation with about 240 mL of water according to the randomized scheme. Ethylenediaminetetraacetic acid-treated blood samples (3 mL) were collected before drug administration and 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 36 hrs after administration. Blood samples were centrifuged (4°C, 3,000 rpm×10 min) and stored at −20°C before analysis.

In the fed condition, after an overnight fast for at least 10 hrs, each volunteer received a single oral 5 mg dosage of the generic or the branded formulation with about 240 mL of water according to the randomized scheme after a standardized high-calorie and high-fat breakfast. The high-calorie and high-fat breakfast (996.1 Kcal) provided in this study met the FDA guidelines,10 which contained 14.26% protein, 50.97% fat, and 34.77% carbohydrate (250 mL of pure milk, 230 g of Caesar chicken roll manufactured by Starbucks®, 24 g of butter and 28 g of waffles). Ethylenediaminetetraacetic acid-treated blood samples (3 mL) were collected before drug administration and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24 and 36 hrs after administration. Blood samples were centrifuged (4°C, 3,000 rpm×10 min) and stored at −20°C before analysis.

The volunteers were instructed to refrain from any intense activity or lying on the bed for a long time after the administration. Consumption of tea, coffee, and other beverages containing alcohol or coffee was restricted in the study, and smoking was also prohibited.

Bioanalysis

Levocetirizine concentrations in plasma were determined by using ultrafast liquid chromatography (Shimadzu® UFLC 20-AD)-tandem mass spectrometry (Sciex QTRAP® 5500) (UFLC-MS/MS) method validated to FDA standards.13 After the sample was completely thawed, 50 μL was added with levocetirizine-d4 (10 μL, internal standard, IS) and acetonitrile (500 μL) in a 96-well plate. The mixture was vortexed for 3 mins and then was centrifuged at 4°C, 3,200 g for 5 mins. 200 μL of the supernatant was evaporated at 40°C with nitrogen, and then the sample was reconstituted with the mobile phase. Finally, 2 μL of the reconstitution was injected into the UFLC-MS/MS system for the analysis. Chromatographic separation was carried out at 40°C on Luna HILIC 200A column (100×2.0 mm, 5 μm) using an isocratic mobile phase system composed of acetonitrile and water (0.4% formic acid, PH: 3.2) (5: 95, v/v) at a flow rate of 0.4 mL/min. The total run time was 3 min. The detection of the analytes was performed in the positive ion and multiple reaction monitoring modes with transitions at m/z 389.2–201.1 for levocetirizine, and at m/z 393.2–201.1 for IS.

There was no label for the generic and branded formulations in the collected plasma samples and only the period of fasting or fed was recorded on the label. This method ensured that the bioanalysis scientist kept the plasma samples as blind. After the analysis was completed, the result was given to the statistical analyst for bioequivalence analysis.

Safety Evaluations

Safety evaluations included adverse events (AEs), serious adverse events (SAEs), vital signs measurements (body temperature, heart rate, seated blood pressure, and respiration rate), physical examination data, laboratory tests (clinical chemistry, hematology, and coagulation tests), 12-lead electrocardiographs, and pregnancy test (female volunteers). Vital signs were assessed at 1 hrs before and at 4, 12, 24, and 48 hrs post-dose. The clinical staff closely monitored AEs throughout the study and graded the AEs as mild, moderate, or severe according to the definitions of “adverse drug reactions”, “adverse events”, and “severe adverse events” (ICH–E2A, Section II-B). If AEs occurred during the study, the volunteers were monitored until the end of AEs/until they are unwilling to continue the follow-up.

Pharmacokinetic, Bioequivalence, And Statistical Analysis

The main pharmacokinetic parameters of the two formulations of levocetirizine were calculated using non-compartmental analysis incorporated in WinNonlin® 7.0 software. Cmax and Tmax were calculated from the clinical trial data. The area under the plasma concentration–time curve (AUC0–36h) and the area under the plasma concentration–time curve extrapolated to infinity (AUC0−∞) were calculated using the trapezoid method. The elimination rate constant (λz) was calculated from the least-squares regression slope of the terminal plasma concentration. Apparent elimination half-life (t1/2) was calculated according to the formula (t1/2 = 0.693/λz). Tmax of the generic and the branded formulations was tested by the non-parametric test. The main pharmacokinetic parameters were transferred by natural logarithm and the significance test was performed by multivariate analysis of variance (ANOVA). If the geometric mean ratio of 90% confidence interval for the log-transformed Cmax and AUC is in the range of 80.00~125.00% (including boundary value),12,14 the generic formulation will assume to be equivalent to the branded formulation. ANOVA included four factors: individual, formulation factors, cycle, and sequence. Pharmacokinetic parameters, AUC0–36h, AUC0–∞, t1/2, Cmax, and Tmax, for levocetirizine under fasting and fed conditions were analyzed by paired-samples t-tests. Data were shown as mean±SD. P<0.05 was considered to be statistically significant.

Results

Fifty-four volunteers were screened in the fasting study and 24 volunteers (18 men and 6 women) enrolled. One volunteer was not treated in the second period and was withdrawn from the study due to sudden emergencies in the family, and one volunteer was discontinued due to ill-health during acupuncture before the administration and was not administered in both the periods. Fifty-four volunteers were screened in the fed study and 25 volunteers (19 men and 6 women) were enrolled in the fed study. One volunteer was withdrawn due to fever on the day of the admission and was not administered in two cycles and was replaced by another volunteer. Finally, a total of 46 volunteers (fasting: 22, fed: 24) completed a two-period crossover study (Figure 1). Baseline characteristics and demographics of volunteers included in the analysis are presented in Table 1. No significant differences in baseline characteristics and demographics of volunteers were found between each group in the study. None of the volunteers showed significant clinical conditions and the laboratory data showed no signs of hepatic or renal insufficiency.

Figure 1

Study participation chart. (A) Fasting group; (B) Fed group.

Table 1

Demographic Characteristics Of Volunteers In The Fasting And Fed Studies (Mean ± SD [Range])

Parameters	Fasting Study (n=24)	Fed Study (n=25)
Sex, male/female	18/6	19/6
Age, years, mean ± SD [range]	24.25 ± 3.91 [18–35]	23.48 ± 1.73 [19–26]
Weight, kg, mean ± SD [range]	62.40 ± 6.40 [52.1–76.5]	62.34 ± 8.01 [49.9–83.6]
Height, cm, mean ± SD [range]	169.92 ± 5.93 [160–179.5]	170.42 ± 6.77 [161.5–189]
BMI, kg/m2, mean ± SD [range]	21.58 ± 1.50 [19.6–25]	21.38 ± 1.62 [19.1–24.1]
12-lead electrocardiography, n (%)
Normal	22 (91.67)	17 (68.0)
Abnormally, no clinical significance	2 (8.33)	8 (32.0)
Abnormally, the clinical significance	0	0
X-ray chest, n (%)
Normal	21 (87.5)	25 (100)
Abnormally, no clinical significance	3 (12.5)	0
Abnormally, the clinical significance	0	0

Abbreviation: BMI, body mass index.

The concentrations of levocetirizine in plasma were determined by the validated LC-MS/MS method. The assay was linear over the range of 1.00–400 ng/mL with the coefficients of variation for intra-day and inter-day less than 6.70% and relative error within ±6.75%. The lower limit of quantification of the method was 1.00 ng/mL. In addition, 76 analyzed samples in the fasting study and 88 analyzed samples in the fed study were selected as incurred sample reanalysis (ISR). All plasma samples met the acceptance criteria. The pass ratio was 100%.

It should be noted that all validation parameters (linearity, accuracy, precision, selectivity, sensitivity, matrix effect, extraction recovery, and stability) of this procedure met the criteria set out in the FDA guidelines.13

Pharmacokinetic Analysis And Bioequivalence

Mean plasma concentration-time profiles of levocetirizine after a single dose of the generic and branded formulations containing 5 mg of levocetirizine for volunteers in fasting and fed states are shown in Figure 2. The main pharmacokinetic parameters are summarized in Table 2. Statistical analysis of pharmacokinetic parameters for volunteers in the fasting and fed studies are described in Tables 3 and 4. The results of the fasting study showed 90% CIs for the geometric mean ratios of Cmax, AUC0–36h, and AUC0-∞ were in the range of 94.75–107.24%, 97.17–102.27%, and 97.13–102.50%. For the fed study, the first sampling point (0.25 h) of one volunteer was Cmax. Therefore, the volunteer was excluded from the bioequivalence analysis. Finally, for the 23 volunteers in the fed condition, the 90% CIs for the geometric mean ratios of Cmax, AUC0–36h, and AUC0-∞ were in the range of 99.98–114.69%, 98.71–103.96%, and 98.36–103.98%, respectively. The results of ANOVA showed that no significant difference existed in the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ between the generic and branded formulations.

Figure 2

Mean(±SD) plasma concentration-time profiles of levocetirizine after a single dose of the generic and branded formulations containing 5 mg of levocetirizine for volunteers in (A) Fasting (n=22) and (B) Fed (n=24) states.

Table 2

Main Pharmacokinetic Parameters For The Generic And Branded Formulations In Fasting And Fed Volunteers

Parameters	Fasting Condition (n=22) Arithmetic Mean ± SD(%CV)		Fed Condition (n=24) Arithmetic Mean ± SD(%CV)
Generic Formulation	Branded Formulation	Generic Formulation	Branded Formulation
aTmax (h)	0.75 (0.33, 1.25)	0.75 (0.33, 1.50)	1.38 (0.25, 3.50)**	1.63 (0.50, 4.00)##
Cmax (ng/mL)	219.23±29.05 (13.25)	219.09±36.78(16.79)	154.13±20.89(13.56)**	145.67±30.61(21.02)##
AUC0–36h (h·ng/mL)	1,737.88±290.85(16.74)	1,750.33±315.88(18.05)	1,501.58±263.24(17.53)*	1,482.16±265.66(17.92)#
AUC0-∞(h·ng/mL)	1,808.71±337.99(18.69)	1,819.22±358.46(19.70)	1,559.76±287.15(18.41)*	1,542.97±294.92(19.11)#
λz (h−1)	0.095±0.017(17.69)	0.095±0.015(15.72)	0.095±0.013(14.18)	0.094±0.015(15.46)
t1/2 (h)	7.50±1.37(18.19)	7.48±1.20(15.98)	7.47±1.01(13.57)	7.50±1.11(14.82)

Notes: aTmax is expressed in median (minimum, maximum). *P<0.05, **P<0.01 for the generic formulation of levocetirizine under fed condition versus that under fasting condition. #p<0.05, ##p<0.01 for the branded formulation of levocetirizine under fed condition versus that under fasting condition.

Table 3

Geometric Mean, Ratio, Intra-Individual Variability, And 90% Confidence Intervals For Levocetirizine In Fasting And Fed Conditions

Parameters	Fasting Condition (n=22)					Fed Condition (n=23)
	Geometric Mean and Ratio			Intra-Individual Variability (%CV)	90% CIs	Geometric Mean and Ratio			Intra-Individual Variability (%CV)	90% CIs
Generic Formulation	Branded Formulation	(Generic/Branded)%	Generic Formulation	Branded Formulation	(Generic/Branded)%
Cmax (ng/mL)	217.229	215.503	100.8	11.90	94.75–107.24	152.178**	142.110##	107.1	13.58%	99.98–114.69
AUC0–36h (h·ng/mL)	1,717.378	1,722.742	99.7	4.90	97.17–102.27	1,486.410*	1,467.359#	101.3	5.11%	98.71–103.96
AUC0-∞ (h·ng/mL)	1,782.428	1,786.390	99.8	5.16	97.13–102.50	1,541.563*	1,524.338#	101.1	5.47%	98.36–103.98

Notes: *P<0.05, **P<0.01 for the generic formulation of levocetirizine under fed condition versus that under fasting condition. #p<0.05, ##p<0.01 for the branded formulation of levocetirizine under fed condition versus that under fasting condition.

Abbreviation: 90% CIs, 90% confidence intervals.

Table 4

P Values Of Multivariate Analysis Of The Generic And The Branded Formulations In Fasting And Fed Conditions

Factors	Fasting Condition (n=22)			Fed Condition (n=23)
LnCmax	LnAUC0-t	LnAUC0-∞	LnCmax	LnAUC0-t	LnAUC0-∞
Sequence	0.533	0.927	0.870	0.634	0.653	0.654
Cycle	0.659	0.246	0.327	0.634	0.010**	0.010**
Formulation factors	0.826	0.836	0.888	0.101	0.402	0.494
Individual	0.023*	0.000**	0.000**	0.035*	0.000**	0.000**

Notes: *P<0.05, **P<0.01 for the generic formulation versus the branded formulation.

Abbreviations: Cmax, the maximal plasma concentration; AUC0-t, the area under the plasma concentration–time curve; AUC0-∞, the area under the plasma concentration–time curve extrapolated to infinity.

Effect Of Food On Pharmacokinetics Of Levocetirizine

The effect of food on the pharmacokinetics of levocetirizine was further explored. The mean plasma concentration-time profiles of levocetirizine in the fasting and fed states are shown in Figure 3. Compared with the fasting condition, the average values of Cmax and AUC for both generic and branded formulations under the fed condition were significantly reduced, and the average values of Tmax were nearly increased to 2-fold (Tables 2 and 3).

Figure 3

Mean(±SD) plasma concentration-time profiles of levocetirizine in fasting (n=22) and fed (n=24) states.

Levocetirizine tablets (5 mg) from the two different companies were well tolerated after administration of single oral dose under fasting and fed conditions in Chinese healthy volunteers. No serious AEs occurred in the study. A total of 47 volunteers entered the safety analysis set. Five cases of AEs occurred in 4 volunteers in the fasting study such as 1 case of elevated lactate dehydrogenase, 1 case of elevated body temperature, 1 case of nausea, 1 case of chest tightness, 1 case of herpes labialis. Four AEs occurred in 3 volunteers in the fed study: 1 case of elevated body temperature, 1 case of elevated lactate dehydrogenase, 1 case of heart rate reduction and 1 case of urinary tract infection. All AEs were mild in nature. Eight cases of AEs were found to be unrelated to the study drugs, and 1 case of AE (herpes labialis) was found to be very unlikely to the study drugs. All AEs were restored to normal at the end of the study.

Discussion

The present study set out with the aim of assessing the bioequivalence of the new generic formulation and the branded formulation in healthy Chinese volunteers, as well as the food-intake effect on the pharmacokinetics of levocetirizine. An open-label randomized single-dose study with double-cycle in a single center was designed. Before the formal study, a pilot study was performed to determine the individual difference of levocetirizine pharmacokinetics in Chinese volunteers, to evaluate the curve range for plasma sample analysis and to optimize the time point of blood sample collection. In the formal study, a total of 22 and 24 volunteers completed fasting and fed studies, respectively.

During sample analysis, quality control was carried out according to the relevant guidelines. The sample preparation was kept as quick and simple as possible. Compared with the chromatogram of the blank plasma sample, no interference of endogenous peaks was observed. The analytical range covered for each sample, and the accuracy for the intra-day/inter-day results was in the acceptable range. The results of all stability studies demonstrated the stability of levocetirizine across all determination steps. In addition, no apparent matrix effect was found to affect the determination of levocetirizine, including the normal, hyperlipemia, and hemolysis matrices. The difference between the concentrations measured by the ISR and the original samples met the requirement of ±20% of the mean values.

Besides the formulation factor, bioequivalence may be affected by other confounders, such as study design, grouping, the period of time, and data processing method. Hence, the ANOVA analysis is employed. ANOVA of the log-transformed data indicated that formulation did not influence the outcome of all main pharmacokinetic parameters in this study. Individual differences are the main factors affecting pharmacokinetic parameters, which may be due to differences in metabolic levels or health status between individuals. According to the guidelines of FDA and CFDA, two different formulations can be considered to be bioequivalent if the 90% CIs of the geometric mean ratios of Cmax, AUC0-t, and AUC0-∞ are contained within 80.0% to 125.0% interval, respectively.12,14 Our results met the regulatory requirements for bioequivalence, and the generic and branded formulations can be confirmed to be in the similar rate and extent of absorption, proving bioequivalence in two formulations under both fasting and fed conditions.

Pharmacokinetic parameters of levocetirizine measured under a fasting condition in the present study were in agreement with the previous studies.2,15 However, most of the published literature is focused on the bioequivalence of branded-to-generic or generic-to-generic substitutions under the fasting condition. There was little information on the effects of food on the bioequivalence and pharmacokinetic parameters of levocetirizine in Chinese. Only levocetirizine prescription information provided some description of the change of the pharmacokinetic parameters after food intake.16 Consistent with the prescription information, our study found that Tmax was significantly delayed and Cmax was significantly decreased after administration with a high-fat meal for both the generic and branded formulations. However, our study failed to demonstrate that food had no effect on the extent of exposure (AUC) of the levocetirizine tablets, as per the prescription information. The present study revealed that the AUC of levocetirizine was significantly decreased under the fed condition for both the generic and branded formulations in the healthy Chinese population. Levocetirizine is orally administered into the gastrointestinal tract, and food in the gastrointestinal tract can affect all aspects of drug absorption, thereby affecting drug absorption and bioavailability. For example, the high-fat food may delay the rate of gastric emptying, change the pH of the gastrointestinal tract to affect the solubility of levocetirizine, or increase the viscosity of gastric juice to hinder the release and dissolution of levocetirizine on the surface of the gastric mucosa.9,17 An explanation, regarding the differences in the impact of food on drug exposure, may be of ethnic differences. Levocetirizine is a weak P-glycoprotein (P-gp) substrate,18 the polymorphism of P-gp gene (ABCB1) exhibited wide ethnic differences in the allele frequency. These nonsynonymous polymorphisms were considered to be clinically important because of their altered ATPase activity and substrate specificity toward different drugs.19 Meanwhile, P-glycoprotein (P-gp) gene could be a contributing factor and possibly a relevant marker for lipid disorder and obesity.20 Therefore, we speculated that there were differences in lipid metabolism between different races, which affected the food–drug interactions, resulting in a decrease in the bioavailability of levocetirizine in Chinese healthy volunteers under high-fat food conditions compared with Western populations.

The safety results suggested both the generic and branded formulations were well tolerated by healthy volunteers under fasting and fed conditions, which was in line with previous research in adults, adolescents, and children with allergic conditions.21–23 There were no serious treatment-related, unexpected or unexplained AEs in either study. Combined with the results of food-intake effects, the high-fat food delayed the absorption rate and reduced the absorption amount of levocetirizine in healthy Chinese volunteers, and there was no difference of AEs between fasting and fed conditions. For antihistamine drugs, it was important to reach peak concentration quickly,24 so it was recommended to administer in the fasting condition.

Conclusions

The present study compared the bioequivalence of a generic formulation of levocetirizine with the originally branded tablet and also investigated the influence of food intake on the pharmacokinetics of levocetirizine. The two formulations demonstrated essentially identical pharmacokinetic profiles and were all well within the FDA/CFDA bioequivalence standards. Our results demonstrate that the newly developed generic formulation may provide a reliable alternative for patients with allergy. Meanwhile, food intake can delay the absorption rate and reduce the bioavailability of levocetirizine in healthy Chinese volunteers. Therefore, administration in the fasting state improves the bioavailability of levocetirizine in Chinese volunteers.